Who
Anil Kapur
Director
Company insider
Files Form 4 as: Director, Verastem; Director, Nurix Therapeutics; EVP, Corp Strategy & CCO, Geron; Chief Commercial Officer, Actinium Pharmaceuticals, Inc. (Delaware).
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $2.0M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 12 Jul 2019
- Last trade
- 21 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 26 May 2026 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 22 May 2025filed 27 May 2025 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 22 May 2025filed 27 May 2025 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —8,333 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Oct 2024filed 16 Oct 2024 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —8,333 at $0.00 | filing |
| 10 Jun 2024filed 12 Jun 2024 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code M | —421,875 at $0.00 | filing |
| 10 Jun 2024filed 12 Jun 2024 | GERN GeronBiotechnology | SEC FORM 4 Code M | $447K421,875 at $1.06 | filing |
| 10 Jun 2024filed 12 Jun 2024 | GERN GeronBiotechnology | SEC FORM 4 Sold | $2.0M421,875 at $4.65 | filing |
| 6 Jun 2024filed 7 Jun 2024 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 14 Feb 2024filed 16 Feb 2024 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 30 Jun 2023filed 30 Jun 2023 | GERN GeronBiotechnology | SEC FORM 4 Code A | $15K7,567 at $2.04 | filing |
| 15 May 2023filed 16 May 2023 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 22 Feb 2023filed 24 Feb 2023 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —625,000 at $0.00 | filing |
| 30 Dec 2022filed 3 Jan 2023 | GERN GeronBiotechnology | SEC FORM 4 Code A | $6,6836,021 at $1.11 | filing |
| 20 Oct 2022filed 24 Oct 2022 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —163,185 at $0.00 | filing |
News
Financial Comparison: Arvinas (NASDAQ:ARVN) & Geron (NASDAQ:GERN)GERN · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name Anil Kapur; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.